Search Within

Diana E Lake

Formats
  1. Meeting Abstract (48)
  2. Journal Article (39)
  3. Book Whole (1)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (89)
  2. Department of Medicine (89)
  3. Solid Tumor Oncology Division (89)
  4. Survivorship Research (89)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (55)
  6. Epidemiology and Biostatistics (48)

More Groups

People
  1. Clifford Hudis (65)
  2. Larry Norton (45)
  3. Gabriella D'Andrea-Carlino (39)
  4. Chau Dang (37)
  5. Monica Fornier (36)
  6. Maura Dickler (33)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (4)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Cancer Research (16)
  3. Breast Cancer Research and Treatment (13)
  4. Clinical Breast Cancer (7)
  5. Clinical Cancer Research (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (20)
  3. Springer (14)
  4. Elsevier Inc. (9)
  5. Oxford University Press (3)
  6. American Medical Association (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Bach, A.; Brufsky, A. M.; Saleh, M. N.; Lake, D.; Dickler, M. N.; D'Andrea, G.; Traina, T. A.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BC): First safety results
    Meeting Abstract

    Dang, C.; Lin, N.; Lake, D.; Theodoulou, M.; Drullinsky, P.; Gorsky, M.; Chen, C.; Norton, L.; Winer, E.; Hudis, C.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and Leukemia Group B
    Journal Article

    Polite, B. N.; Cirrincione, C.; Fleming, G. F.; Berry, D. A.; Seidman, A.; Muss, H.; Norton, L.; Shapiro, C.; Bakri, K.; Marcom, K.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer
    Journal Article

    Yalamanchili, K.; Lalmuanpuii, J.; Waheed, F.; Farjami, S.; Kancherla, R. A. M.; Qureshi, Z.; Hoang, A.; Khaled, Y.; Lake, D.; Puccio, C.; more...
    Anticancer Research (2008)

    Fulltext@MSK | Save
  • Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
    Journal Article

    Traina, T. A.; Poggesi, I.; Robson, M.; Asnis, A.; Duncan, B. A.; Heerdt, A.; Dang, C.; Lake, D.; Moasser, M.; Panageas, K.; more...
    Breast Cancer Research and Treatment (2008)

    Fulltext@MSK | Save
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840
    Journal Article

    Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Muss, H.; Marcom, P. K.; Gipson, G.; Burstein, H.; Lake, D.; Shapiro, C. L.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Journal Article

    Dang, C.; D'Andrea, G.; Lake, D.; Sugarman, S.; Fornier, M.; Moynahan, M. E.; Gilewski, T.; Hurria, A.; Mills, N.; Troso-Sandoval, T.; more...
    Clinical Breast Cancer (2008)

    Fulltext@MSK | Save